Cis-platinum-induced renal sodium wasting

Area of Science:

• Pediatric Oncology
• Nephrology
• Clinical Pharmacology

Background:

• Malignant ovarian germ cell tumors require aggressive treatment, often involving platinum-based chemotherapy.
• Cis-platinum is a cornerstone chemotherapeutic agent, but its use is associated with significant toxicities, including nephrotoxicity and electrolyte disturbances.

Observation:

• A pediatric patient treated with cis-platinum developed severe hyponatremia, hypomagnesemia, and hypocalcemia.
• Renal sodium wasting was identified as the cause of hyponatremia.
• Hyponatremia recurred upon cessation of cis-platinum, even after electrolyte normalization, particularly during periods of physiological stress.

Findings:

• Cis-platinum-induced hypomagnesemia is linked to renal tubular dysfunction and magnesium wasting.
• The study proposes a similar mechanism of renal tubular dysfunction leading to sodium wasting as the cause of cis-platinum-induced hyponatremia.
• Electrolyte imbalances may persist or recur even after treatment cessation, especially under stress.

Implications:

• Understanding the renal mechanisms of cis-platinum toxicity is crucial for managing pediatric cancer patients.
• Monitoring and managing electrolyte disturbances, particularly hyponatremia and hypomagnesemia, is essential during and after cis-platinum chemotherapy.
• Further research into cis-platinum's effects on renal tubular function may lead to improved supportive care strategies.